Tralokinumab in the Era of Disruption in Atopic Dermatitis
Gain valuable insights from three atopic dermatitis (AD) specialists who specifically consider one of the newest systemic therapies that targets the cytokine IL-13, a key cytokine involved in the pathogenesis of AD.
